pre-IPO PHARMA

COMPANY OVERVIEW

Cullinan Oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. Sourced from the Cullinan dry lab as well as external collaborators, Cullinan’s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.


LOCATION

  • Cambridge, MA, USA

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://www.cullinanoncology.com


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    f2-ventures mpm-capital


    PRESS RELEASES


    Dec 17, 2020

    Cullinan Oncology Completes $131.2 Million Series C Financing


    Oct 29, 2020

    Cullinan Oncology Appoints Jeff Trigilio as Chief Financial Officer


    Sep 15, 2020

    Cullinan Oncology, German Cancer Research Center (DKFZ) and the University of Tübingen Announce the Formation of Cullinan Florentine to Develop CLN-049, a Novel Bispecific Antibody for AML


    Jul 22, 2020

    Cullinan Oncology Launches Cullinan Amber to Pioneer Next-Generation Cytokine Fusion Proteins for Cancer Therapy


    Jun 11, 2020

    Cullinan Oncology and PDI Therapeutics Join Forces to Bring Novel, First-In-Class Immuno-Oncology Antibody into the Clinic through a $26M Series A Financing


    For More Press Releases


    Google Analytics Alternative